These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33662688)

  • 1. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
    Fukumoto T; Horita N
    Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
    [No Abstract]   [Full Text] [Related]  

  • 2. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.
    Bafaloukos D; Gazouli I; Bousmpoukea A; Molfeta A; Chatzichristou E; Samonis G; Vathiotis I
    Immunotherapy; 2024; 16(14-15):937-942. PubMed ID: 39258778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
    Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
    [No Abstract]   [Full Text] [Related]  

  • 6. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
    BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
    J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
    Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
    J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
    [No Abstract]   [Full Text] [Related]  

  • 10. Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel.
    Grote C; Bohne AS; Blome C; Kähler KC
    J Cancer Res Clin Oncol; 2024 Oct; 150(10):454. PubMed ID: 39387946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
    Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
    J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
    [No Abstract]   [Full Text] [Related]  

  • 12. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
    Konishi K; Okamoto M; Tokumitsu R; Yano M; Nasu K; Kobayashi E
    Med Mol Morphol; 2024 Jun; 57(2):83-90. PubMed ID: 38289480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid atrophy and pancreatic involution after cancer Immunotherapy.
    Haupt F; Prosch H; Ebner L
    Rofo; 2020 Jul; 192(7):688-690. PubMed ID: 32193884
    [No Abstract]   [Full Text] [Related]  

  • 15. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

  • 16. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
    Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
    Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
    Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
    Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
    Joshi K; Atwal D; Ravilla R; Pandey Y; Yarlagadda N; Kakadia S; Makhoul I; Hutchins L; Mahmoud F
    Perm J; 2020; 24():. PubMed ID: 32097116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nivolumab in melanoma.
    Gomes F; Serra-Bellver P; Lorigan P
    Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carroll BT; Theuner J; Li S; Fu P; Kirkwood JM
    JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.